Log in to search using one of your social media accounts:

 

Three UCLA professors named fellows of the American Association for the Advancement of Science
Two  doctors and a dentist from UCLA have been selected as 2017 fellows of the American Association for the Advancement of Science. They are among 396 members awarded this honor by the AAAS for their scientifically or socially distinguished efforts to advance science or its applications.New fellows will be presented with an official certificate and a gold and blue rosette pin, representing science and engineering, on Feb. 17, 2018, at the association ’s annual meeting in Austin, Texas, and formally announced in the “AAAS News and Notes” section of the journal Science on Nov. 24.UCLA ’...
Source: UCLA Newsroom: Health Sciences - November 20, 2017 Category: Universities & Medical Training Source Type: news

Drug maker pulls off rare feat — literally — with 1st drug approval
The North Bay company was started just seven years ago, went public nearly three years ago and on Wednesday landed FDA approval of its first drug, a treatment for a ultra-rare disease known as MPS VII that will cost $375,000 a year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 16, 2017 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Drug maker pulls off rare feat — literally — with 1st drug approval
The North Bay company was started just seven years ago, went public nearly three years ago and on Wednesday landed FDA approval of its first drug, a treatment for a ultra-rare disease known as MPS VII that will cost $375,000 a year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 16, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

Indian girl's head doubles in size due to rare disease
Reshmi Marak's head started growing a month after birth and is now 68cms in circumference. Her father Amrit, from India, is a daily labourer earning about Rs4,000 ( £45) a month. (Source: the Mail online | Health)
Source: the Mail online | Health - November 15, 2017 Category: Consumer Health News Source Type: news

Boy with rare disease gets new skin with gene therapy
"We were forced to do something dramatic because this kid was dying," his doctor said (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 9, 2017 Category: Consumer Health News Source Type: news

Congress Weighs Repeal of Tax Credit for Rare Disease Drugs
Long untouchable, the incentive for development of orphan drugs is now a Republican target as lawmakers consider a broad tax overhaul. (Source: NYT Health)
Source: NYT Health - November 8, 2017 Category: Consumer Health News Authors: KATIE THOMAS and SHEILA KAPLAN Tags: Drugs (Pharmaceuticals) Federal Taxes (US) Corporate Taxes Tax Credits, Deductions and Exemptions Biotechnology and Bioengineering House of Representatives Senate Medicine and Health United States Politics and Government Source Type: news

9-year-old boy with rare disease now has engineered skin covering 80% of his body
For a soccer-playing, holiday-loving boy on the brink of death from a rare inherited skin disease, doctors have accomplished a feat of genetic engineering, surgical stamina and raw nerve.Infections arising from blisters and sores had destroyed 60% of his skin. Just 7 years old when he arrived... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - November 8, 2017 Category: Science Authors: Melissa Healy Source Type: news

Boy with rare disease gets most of skin replaced through gene therapy
Desperate to save a seven-year-old boy's life, doctors used experimental gene therapy to create new skin in a lab after skin graft attempts had failed. (Source: CBC | Health)
Source: CBC | Health - November 8, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

Genetically Altered Skin Saves A Boy Dying Of A Rare Disease
An inherited disease called epidermolysis bullosa destroyed the 7-year-old's skin. Scientists grew new skin in the lab without the genetic flaw, and replaced 80 percent of his skin. He is thriving.(Image credit: CMR Unimore/Nature ) (Source: NPR Health and Science)
Source: NPR Health and Science - November 8, 2017 Category: Consumer Health News Authors: Richard Harris Source Type: news

Police save lives every day, just not this way — a liver for Sloan
Sloane and Lt. Tenney A police officer’s job is all about action and reaction. “We see something, react to it and, typically, it’s over quickly,” says Lt. Steve Tenney of the Keene, New Hampshire, Police Department. But on the morning of Sept. 8, while Steve lay in a hospital bed at Lahey Hospital & Medical Center in Burlington, Massachusetts, action/reaction wasn’t part of the equation. This time, there was time to think. Even so, the decision to donate a piece of his liver to save Sloan — a baby he’d never even met — was made without hesitation. “I did what anyone...
Source: Thrive, Children's Hospital Boston - November 8, 2017 Category: Pediatrics Authors: Emily Williams Tags: Diseases & Conditions Our Patients’ Stories biliary atresia Dr. Christine Lee Dr. Heung-Bae Kim Dr. Khashavar Vakili Liver transplant Liver Transplant Program living donor Source Type: news

Parent-to-parent: Tips for Home Parenteral Nutrition families
Four-year-old Thomas Onorato is a young zoologist at heart. Often seen with binoculars in hand, the adventurous preschooler is particularly drawn to bird watching. He enjoys talking about his feathery friends and studying their beauty and habitat. Thomas’ love of animals runs so deep that he says he wants to be a veterinarian when he grows up. “Thomas is obsessed with animals. It’s his love,” says his mother, Melissa. Beyond his quest to care for animals, Thomas has two other important missions — to manage the rare condition, microvillus inclusion disease (MVID) and receive the ...
Source: Thrive, Children's Hospital Boston - November 7, 2017 Category: Pediatrics Authors: Maureen McCarthy Tags: Our Patients’ Stories Parenting Dr. Bram Raphael home parenteral nutrition Microvillus inclusion disease Source Type: news

Hormone Loss Prevents Obesity and Diabetes in Mice
Asprosin-involved in a rare disease called neonatal progeroid syndrome-targets neurons to stimulate appetite, and blocking the hormone wards off weight gain in rodents. (Source: The Scientist)
Source: The Scientist - November 6, 2017 Category: Science Tags: Daily News Source Type: news

House GOP Aims to Pull Tax Credits for Orphan Drugs House GOP Aims to Pull Tax Credits for Orphan Drugs
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

The need to incentivise antibiotic research | Letters
Thoughtful governmental action can make development of new drugs for small patient populations viable, saysProf David Roblin,whileDr Georgina Crayford responds to an article on efforts to cut the use of antibiotics in farmingDavid Cox reports on the “war on bugs” and development of “superantibiotics” (23 October). A blunderbuss is effective against the enemy, but what of the collateral damage? We humans contain more bacteria than human cells – our microbiome – which are key for many aspects of health. A more modern approach is to identify precisely the bacteria responsible for a dis...
Source: Guardian Unlimited Science - November 2, 2017 Category: Science Authors: Letters Tags: Antibiotics Pharmaceuticals industry Health Farming Environment Society UK news Business Medical research Science Source Type: news

Alnylam shares hit all-time high as rare disease drug continues to impress
Alnylam Pharmaceuticals added more than $1.5 billion to its market cap on Thursday after unveiling new data from a closely watched trial of its lead rare disease drug, which appeared to outperform a competitor ’s drug targeting the same disorder. Alnylam (Nasdaq: ALNY) reported new details from a Phase 3 trial of patisiran, a potential treatment for a disease called amyloidosis ­that affects around 10,000 people. The company previously said in September that the study had met all of its goals,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Gene Therapy, New Drug Fight Rare Disease in Kids
Two innovative new therapies for spinal muscular atrophy (SMA) type 1 have proven highly effective in clinical trials, researchers report. (Source: WebMD Health)
Source: WebMD Health - November 1, 2017 Category: Consumer Health News Source Type: news

AstraZeneca licenses genetic disease drug to Mereo BioPharma
LONDON (Reuters) - Mereo BioPharma has agreed a licensing deal and acquisition option for a rare disease drug from AstraZeneca as the big drugmaker continues to divest non-core assets. (Source: Reuters: Health)
Source: Reuters: Health - October 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Shire to sell 100-employee Milford site as part of manufacturing slim-down
Rare disease drugmaker Shire, one of the state ’s biggest life science employers, is in active negotiations to sell one of its manufacturing sites in Milford, according to a top executive. Shire (Nasdaq: SHPG) announced as part of its third quarter earnings on Friday that it plans to implement a cost-cutting program targeting its manufacturin g operations. In an interview, the company’s head of technical operations, Matt Walker, told the Business Journal that Shire is divesting five of its 17… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 27, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Say “ Yes! ” Whenever Possible
To celebrate Medical Librarian’s Month we have invited medical librarians in our region to submit some information about who they are and the work that they do as medical librarians. Today we hear from a hospital librarian in Oregon! Judith with Mr. Gross Mouth Who am I? Judith Hayes, MLS Where do I work? Tuality Healthcare in Hillsboro, OR I started work as a medical librarian at Tuality Healthcare in Hillsboro, OR, on April 15, 1994.  Almost 24 years later, I am approaching retirement in just a few short weeks with anticipation and dread. It’s been amazing.  I have loved my job.  It feeds my se...
Source: Dragonfly - October 26, 2017 Category: Databases & Libraries Authors: Carolyn Martin Tags: News from Network Members Medial L Medical Librarians Month Source Type: news

Society for Participatory Medicine Adds Pulse Infoframe ’ s Digital Tool-Set & Supercharges Corporate Member Benefit Offering
    NEWS / FOR IMMEDIATE RELEASE Society for Participatory Medicine Adds Pulse Infoframe’s Digital Tool-Set and Supercharges Corporate Member Benefit Offering. Patient Portals, Evidence-Based Patient Reported Outcome Measures, Health Registries, Real Time Analytics, & Data Visualization Capabilities Offering Augments Member Benefit (Boston, Mass. and London, Ont., Oct 25, 2017) Senior executives from the Society for Participatory Medicine, the preeminent organization in promoting true partnerships between patients and healthcare professionals, and Pulse Infoframe Inc., a leading cloud-based health car...
Source: Society for Participatory Medicine - October 25, 2017 Category: General Medicine Authors: John Grohol Tags: News News Releases Source Type: news

The Guardian view on gene therapy: money well spent | Editorial
A rare and fatal disease will be now treated on the NHS. But the real problems come from common and unglamorous complaintsThe NHS is tofund a very expensive treatment for a very rare but terrible childhood disorder that leaves babies condemned to life in a sterile bubble. This is a triumph for medical science but it should also provoke some deep and careful thought. The treatment in question, strimvelis, qualifies as the second most expensive drug ever put on the market (the only one more expensive waswithdrawn due to lack of demand). A single dose costs nearly £500,000 plus VAT, and can only be administere...
Source: Guardian Unlimited Science - October 23, 2017 Category: Science Authors: Editorial Tags: Medical research Stem cells Genetics Biology Science NHS Health Society Children UK news Source Type: news

The Digital Disruption
“We are now marketers in a data-driven world,” says Steve Mason, Multichannel and Marketing Cloud Expert at Sales Force. His epochal address, aimed squarely at the pharma industry during eyeforpharma’s Marketing and Customer Innovation event last year, could not have been clearer: get digitall y savvy or get left behind.It ’s an unassailable argument. Strides in digital innovation have redefined the ways we organise our time and space. The proliferation of digital channels - combined with the free flow of information readily available - has made the customer experience more integrated and personalis...
Source: EyeForPharma - October 23, 2017 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

What is Usher Syndrome?
Discussion Over 7000 diseases are considered rare disorders according to the National Organization for Rare Disorders® (NORD, rarediseases.org). NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. They have information on about 1200 rare diseases on their website (https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/). Hearing loss (HL) is not rare and is a common problem across the ages. It affects 360 million people worldwide which is about 5% of the population. There are many causes of hearing loss an...
Source: PediatricEducation.org - October 23, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Mallinckrodt adds New Jersey campus employing nearly 500
Mallinckrodt Pharmaceuticals on Monday officially opened a new campus in New Jersey for its specialty brands division that will employ nearly 500. The new offices in Bedminster, New Jersey, will provide support for the company's hospital therapies and autoimmune and rare diseases businesses. Mallinckrodt renovated 190,000 square feet of office space on the campus and is now occupying more than 80 percent of the building, which was designed to accommodate additional growth. "Bedminster has proved… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 17, 2017 Category: Health Management Authors: Angela Mueller Source Type: news

Teen suffering from rare disease to participate in pageant
Macey Brietenback (pictured), 16, from Maryland, lives with a rare, potentially-fatal disease called visceral myopathy, but she will soon participate in a beauty pageant. (Source: the Mail online | Health)
Source: the Mail online | Health - October 16, 2017 Category: Consumer Health News Source Type: news

QOL Medical Launches a First-of-its-kind Augmented Reality App in the...
QOL Medical LLC, a rare-disease pharmaceutical company, today announced the launch of a first-of-its-kind app, GSID AR, providing users with augmented reality (AR) technology to explore both a healthy...(PRWeb October 16, 2017)Read the full story at http://www.prweb.com/releases/GSIDARApp/2017/prweb14806433.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 16, 2017 Category: Pharmaceuticals Source Type: news

Nigeria: There Are Reports That Monkeypox Has Resurfaced in Nigeria. What You Need to Know
[The Conversation Africa] The outbreak of a rare disease suspected to be Monkeypox is raising fears of an imminent epidemic in Nigeria. Infected people break out in a rash that looks a lot like chicken pox. But the fever, malaise, and headache from Monkeypox are usually more severe than in chicken pox infection.The disease can spread quickly and in previous outbreaks one of 10 people have died. The first suspected cases were reported in Bayelsa state in south Nigeria in late September. Since then suspected cases have been reported (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 13, 2017 Category: African Health Source Type: news

Nigeria:There Are Reports That Monkeypox Has Resurfaced in Nigeria. What You Need to Know
[The Conversation Africa] The outbreak of a rare disease suspected to be Monkeypox is raising fears of an imminent epidemic in Nigeria. Infected people break out in a rash that looks a lot like chicken pox. But the fever, malaise, and headache from Monkeypox are usually more severe than in chicken pox infection.The disease can spread quickly and in previous outbreaks one of 10 people have died. The first suspected cases were reported in Bayelsa state in south Nigeria in late September. Since then suspected cases have been reported (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 13, 2017 Category: African Health Source Type: news

Expanded Access: FDA describes efforts to ease application process
By: Scott Gottlieb, M.D. FDA has a long history of supporting patient access to investigational new treatments. This includes working with drug and device companies through the clinical trial process that may lead to FDA approval of the treatment. We also offer expanded access programs that provide investigational drugs and devices to patients with serious conditions (generally prior to product approval), when there is no therapeutic alternative. Each year, FDA receives over 1,000 applications for the treatment of patients through expanded access, also known as compassionate use, and the agency authorizes the vast majority...
Source: Mass Device - October 12, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog FDA Voice Source Type: news

Massachusetts boy with rare disease signed to hockey team
Coleman Walsh, a 10-year-old boy from Massachusetts (pictured), lives with a rare genetic condition called Williams syndrome. Today he is being signed to Babson College's hockey team. (Source: the Mail online | Health)
Source: the Mail online | Health - October 11, 2017 Category: Consumer Health News Source Type: news

UMass Medical launching rare disease institute with $10M gift from Chinese businessman
The University of Massachusetts Medical School is forming a new institute to study rare diseases, thanks to a $10 million gift from the Li Weibo Charitable Foundation in China. Li Weibo, who established the Li Weibo Charitable Foundation in 2013 to support biomedical research and education, plans to donate half his wealth to the foundation. In addition to the $10 million gift to the medical school, he is also donating $750,000 to establish an annual scholarship for up to five doctoral students… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 10, 2017 Category: American Health Authors: Jessica Bartlett Source Type: news

UMass Medical launching rare disease institute with $10M gift from Chinese businessman
The University of Massachusetts Medical School is forming a new institute to study rare diseases, thanks to a $10 million gift from the Li Weibo Charitable Foundation in China. Li Weibo, who established the Li Weibo Charitable Foundation in 2013 to support biomedical research and education, plans to donate half his wealth to the foundation. In addition to the $10 million gift to the medical school, he is also donating $750,000 to establish an annual scholarship for up to five doctoral students… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 10, 2017 Category: Biotechnology Authors: Jessica Bartlett Source Type: news

​Merck takes stake in small Cambridge rare disease biotech, lifting shares
KalVista Pharmaceuticals, a small Cambridge biotech with a pair of rare disease treatments in early-stage studies, saw its market value soar on Tuesday after announcing that drug giant Merck has taken a 10 percent stake in the company. KalVista (Nasdaq: KALV) said it had struck a deal with Merck (NYSE: MRK) under which the companies will collaborate to develop treatments for diabetic macular edema, or DME, a complication of diabetes in which fluid builds up in the retina. Under the agreement, KalVista… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 10, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Experimental treatment helps toddler with rare disease
The 2-year-old is the youngest child in the country receiving this treatment to fight Niemann-Pick disease type C, a rare and deadly disease (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 9, 2017 Category: Consumer Health News Source Type: news

5 minutes with John Boyle, CEO, Immune Deficiency Foundation
The nonprofit benefits people who are dealing with rare diseases that impact the body's immune system. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 9, 2017 Category: American Health Authors: Jonathan Munshaw Source Type: news

Rituximab Aids in IgA Vasculitis (CME/CE)
(MedPage Today) -- Effective in refractory cases of this rare disease, small study suggests (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 6, 2017 Category: Primary Care Source Type: news

FDA awards 15 grants for clinical trials to stimulate product development for rare diseases
The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 6, 2017 Category: American Health Source Type: news

FDA awards six grants for natural history studies in rare diseases
The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to inform medical product development by better understanding how specific rare diseases progress over time. One potential application of these studies is the opportunity to eventually use natural history models to augment the need for placebo arms in studies of drugs that target very rare disease, where trial recruitment can be challenging. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 6, 2017 Category: American Health Source Type: news

FDA awards 15 grants for clinical trials to stimulate product development for rare diseases
The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country. (Source: World Pharma News)
Source: World Pharma News - October 6, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA awards six grants for natural history studies in rare diseases
The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to inform medical product development by better understanding how specific rare diseases progress over time. (Source: World Pharma News)
Source: World Pharma News - October 6, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

​Shire officially inks sublease for former Ariad site in Cambridge
The agreement is part of the rare disease drugmaker's plan to expand its presence in Kendall Square. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 5, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Ex-Genzyme head Meeker to lead Flagship drug startup KSQ
Since leaving his longtime post as head of Cambridge rare disease giant Sanofi Genzyme, David Meeker has been looking to join a company that, as he put it in an interview, “has the ability to make a difference.” Meeker, who departed Genzyme in June after more than 23 years, didn't have to look very long — or far. On Monday, KSQ Therapeutics, a cancer drug startup that is backed by Flagship Pioneering and located about a mile from the Genzyme building in Kendall Square, announced that it had… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 2, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

NBA stars surprise eight-year-old fan with rare disease
Case Hogan (pictured right) of Tennessee has a disease that typically kills children by age 15. A basketball fan, Hogan was surprised by NBA stars such as Blake Griffin (left) and Lonzo Ball (right). (Source: the Mail online | Health)
Source: the Mail online | Health - September 28, 2017 Category: Consumer Health News Source Type: news

The benefits & dangers when genetic testing companies partner with orphan drug developers
(Mary Ann Liebert, Inc./Genetic Engineering News) Pharmaceutical companies developing Orphan Drugs are increasingly partnering with direct-to-consumer (DTC) genetic testing firms to identify individuals with rare diseases, in a trend that is raising concerns related to privacy, drug costs, and rising healthcare-related financial burden for consumers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 27, 2017 Category: International Medicine & Public Health Source Type: news

Heritage Biologics launches innovative HBnow virtual care program
Heritage Biologics, a leader in Rare Disease Outcomes Management (RDOM), is announcing the launch of their HBnow virtual care program.(PRWeb September 27, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14741708.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 27, 2017 Category: Pharmaceuticals Source Type: news

In A First, Pfizer Spins Out Biotech Firm With $103 Million In Funding
Pfizer is announcing today that it is spinning out a new company, SpringWorks Therapeutics, to develop several drugs for rare diseases that the drug giant did not want to move forward internally. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 25, 2017 Category: Pharmaceuticals Authors: Ellie Kincaid, Forbes Staff Tags: NYSE:PFE Source Type: news

Nigeria: No Hope We Will Survive
[Vanguard] Decades ago, cancer was among rare diseases in Nigeria. Today the story has changed. The situation is so bad that almost every day there are new cases in various hospitals across the country. It is almost becoming like malaria. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 24, 2017 Category: African Health Source Type: news

Advisory Panel on Rare Disease Fall 2017 Meeting
Wednesday, September 27, 2017; via webinar. Members of the public are welcome to listen in on the meeting. (Source: HSR Information Central)
Source: HSR Information Central - September 22, 2017 Category: International Medicine & Public Health Source Type: news

Why Scrip Awards Have Shortlisted orphan reach, a CRO That Develops...
orphan reach, a leading Contract Research Organization (CRO) dedicated to the global clinical development of orphan drugs for rare diseases, has been selected as a finalist for the Scrip Awards 2017.(PRWeb September 22, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14711502.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 22, 2017 Category: Pharmaceuticals Source Type: news